Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Grail Inc GRAL

Healthcare Biotechnology
GRAIL, Inc., formerly GRAIL, LLC, is a healthcare company, which is engaged in saving lives and shifting the paradigm in early cancer detection. It is focused on alleviating the global burden of cancer by using next-generation sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its... see more

Recent & Breaking News (NDAQ:GRAL)

    GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    PR Newswire 1 day ago

    GRAIL to Participate in Upcoming Investor Conferences

    PR Newswire November 19, 2024

    GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study

    PR Newswire November 18, 2024

    GRAIL Reports Third Quarter 2024 Financial Results

    PR Newswire November 12, 2024

    GRAIL to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

    PR Newswire November 4, 2024

    GRAIL to Announce Third Quarter 2024 Financial Results

    PR Newswire October 29, 2024

    GRAIL Presents Initial Results From REFLECTION Real-World Evidence Study of Galleri® Multi-Cancer Early Detection (MCED) Test at the Early Detection of Cancer Conference

    PR Newswire October 23, 2024

    GRAIL Appoints Sarah Krevans to Board of Directors

    PR Newswire October 21, 2024

    GRAIL ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(c)(4)

    PR Newswire August 30, 2024

    Results of GRAIL's Galleri® Multi-Cancer Early Detection Blood Test in Prostate Cancer Published in JCO Precision Oncology

    PR Newswire August 29, 2024

    GRAIL to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

    PR Newswire August 21, 2024

    GRAIL Reports Second Quarter 2024 Financial Results and Provides a Strategic Update

    PR Newswire August 13, 2024

    Wheels Up Announces Gregory Summe to Join Board of Directors

    PR Newswire August 8, 2024

    GRAIL to Announce Second Quarter 2024 Financial Results

    PR Newswire July 31, 2024

    GRAIL Announces First Participant Enrolled in REACH Study Evaluating Clinical Impact of Galleri® Multi-Cancer Early Detection (MCED) Test in the Medicare Population

    PR Newswire July 18, 2024

    GRAIL Advances the Galleri® Registrational Clinical Trial Program

    PR Newswire July 15, 2024